A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

sunitinib malate dose escalation

sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).

DRUG

sunitinib malate

sunitinib 50mg daily on Schedule 4/2

Trial Locations (9)

13385

CHU de La Timone, Hopital enfants, Marseille

Hopital d'Enfants de la Timone, Marseille

Hopital de la Timone, Marseille

90027

Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles

02115

Children's Hospital Boston, Boston

02215

Dana-Farber Cancer Institute, Boston

613 00

Fakultni nemocnice Brno, Brno

625 00

FN Brno, Brno

656 33

Masarykuv onkologicky ustav, Brno

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01396148 - A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | Biotech Hunter | Biotech Hunter